GCAN Greater Cannabis Company Inc (PK)

GammaCan International, Inc. (OTCBB: GCAN) today announced that scientists from Tel Ha'Shomer Hospital in Tel Aviv and GammaCan will present an abstract at the 5th Annual Congress on Autoimmunity in Sorrento Italy from November 29th through December 3rd, 2006. The study, supported by GammaCan International, under the direction of Professors Yehuda Shoenfeld, and Miri Blank is entitled "IgG Decreases Lung Metastatic Potential of Murine (mouse) Colon Carcinoma." The researchers will present data examining IgG's (GCAN101) efficacy in inhibiting the proliferation and metastatic capacity of colon cancer in a mouse model. Results suggesting that IgG may be considered a supportive therapy for the inhibition of colon carcinoma metastases will be included in the abstract discussion. Prof. Jacob Nusbacher, Director of Medical & Scientific Affairs at GammaCan commented: "This study confirms other studies that have been done by GammaCan scientists on other cancers. In the aggregate, these studies lay the groundwork for the continued development of immunoglobulin-based anti-cancer therapies, such as we are now doing with our next generation product, the new anti-melanoma drug, VitiGam." About GCAN101 GCAN101 (standard IgG) is currently completing an open label, 30 patient phase II trial designed to evaluate the efficacy and safety of IgG therapy in cancer patients who failed all current therapies. The trial is enrolling patients with colon cancer, melanoma and prostate cancer. The colon and melanoma arms are fully enrolled. About VitiGam: VitiGam is GammaCan's second generation intravenous IgG-based product and a first-in-class anti-cancer immunotherapy. GammaCan plans on having VitiGam to enter phase I/II testing under a US IND in the near future after it recently held a pre-IND meeting with the FDA. VitiGam is being designed to target metastatic melanoma patients with Stage III and IV melanoma. VitiGam is an IgG product that is different from standard IgGs: It is manufactured from the plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population. GammaCan scientists have shown that this "enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma activity in both in vitro and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to provide (1) anti-melanoma activity directed specifically against malignant melanoma cells and (2) non-specific anti-cancer activity - as is the case with IgG in general. About GammaCan GammaCan is focusing on the commercialization of an innovative anti-cancer immunotherapy to treat metastatic cancer. GammaCan's platform is based on IgG, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. IgG works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. GammaCan is developing VitiGam, its second generation program. VitiGam is an IgG derived from the plasma of vitiligo donors and is being developed to treat malignant melanoma. GammaCan owns, and has applied for US patent protection covering the use of IgG and vitiligo-derived IgG (VitiGam). For more information about GammaCan visit www.GammaCan.com or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free 1-866-308-0396 (from North America). Safe Harbor Statement: Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IgG into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early state medical research and development companies filed with the SEC on Edgar.